---
firstreceived_date: November 20, 2013
is_fda_regulated: 'No'
reference: []
overall_contact_backup:
  first_name: 
  last_name: Daniela Rubino
  middle_name: 
  phone_ext: 
  phone: 
  degrees: 
  email: daniela.rubino@ukbb.ch
completion_date:
  attributes:
    type: Anticipated
  value: December 2016
responsible_party: {}
firstreceived_results_date: 
is_section_801: 
detailed_description:
  textblock: |-
    This is a single center, randomized, double-blind, placebo controlled study. The study
          medication consists of L-citrulline and metformin, respectively placebo given orally; 2.5 g
          L-citrulline or placebo will be given 3 times daily, metformin containing 250 mg or placebo
          will be administered 3 times daily. The duration of the study is 26 weeks and comprehends
          one screening and three study visits.
link: []
has_expanded_access: 'No'
id: NCT01995032
intervention:
- intervention_name: 750 mg metformin and 7.5 g L-citrulline daily p.o.
  other_name: []
  description: 
  arm_group_label:
  - metformin and L-citrulline
  intervention_type: Drug
- intervention_name: Placebo
  other_name: []
  description: 
  arm_group_label:
  - Placebo
  intervention_type: Drug
source: University Hospital, Basel, Switzerland
eligibility:
  gender: Both
  maximum_age: 10 Years
  sampling_method: 
  minimum_age: 7 Years
  study_pop: {}
  criteria:
    textblock: |-
      Inclusion Criteria:

                -  Molecular diagnosis of DMD

                -  Patients 7 - 10 years of age at time of screening

                -  Ambulant

                -  Ability to walk 150 m in the 6 min walking distance (6MWT)

                -  D1 subdomain of the MFM scale >40%

                -  stable treatment with steroids for >6 months or steroid na√Øve patients

              Exclusion Criteria:

                -  Previous (3 months or less) or concomitant participation in another therapeutic trial

                -  Use of L-citrulline, L-arginine or metformin within the last 3 months

                -  Known individual hypersensitivity to L-citrulline or metformin

                -  known or suspected malignancy

                -  Other chronic disease or clinical relevant limitation of renal, liver, heart function
                   according to discretion of investigator

                -  start of cortisone treatment or change in dosage <6 months prior to screening
  healthy_volunteers: 'No'
removed_countries: {}
other_outcome: []
primary_completion_date:
  attributes:
    type: Anticipated
  value: June 2016
last_injected: '2015-09-26T00:06:45.885Z'
intervention_browse:
  mesh_term:
  - Metformin
target_duration: 
number_of_arms: '2'
start_date: October 2013
why_stopped: 
id_info:
  org_study_id: DMD02
  secondary_id: []
  nct_alias: []
  nct_id: NCT01995032
acronym: 
arm_group:
- description: 7.5 g L-citrulline p.o. and 750 mg metformin p.o. per day (3x 2.5 g,
    respectively 3x 250 mg) for 26 weeks
  arm_group_label: metformin and L-citrulline
  arm_group_type: Experimental
- description: metformin placebo and L-citrulline placebo 3 times daily p.o. for 26
    weeks
  arm_group_label: Placebo
  arm_group_type: Placebo Comparator
sponsors:
  collaborator: []
  lead_sponsor:
    agency: University Hospital, Basel, Switzerland
    agency_class: Other
secondary_outcome:
- safety_issue: 'No'
  time_frame: baseline to week 26
  description: 
  measure: Mean change of MFM total score, the D2, and D3 MFM subscores
- safety_issue: 'No'
  time_frame: baseline to week 26
  description: 
  measure: Mean change of six minute walking distance (6MWD)
- safety_issue: 'No'
  time_frame: baseline to week 26
  description: 
  measure: Change of quantitative muscle MRI (Magnetic Resonance Imaging) including
    muscle fat content (MFC) and T2 times of thigh muscles
- safety_issue: 'No'
  time_frame: baseline to week 26
  description: 
  measure: Change in the plasma/urine concentration for markers of muscle necrosis,
    oxidative stress, nitrosative stress, and change of microRNA (miRNA)
- safety_issue: 'No'
  time_frame: baseline to week 26
  description: 
  measure: Mean change of quantitative muscle force (QMT) of knee extension and elbow
    flexion using hand held dynamometry (HHD)
study_type: Interventional
biospec_retention: 
overall_status: Recruiting
primary_outcome:
- safety_issue: 'No'
  time_frame: baseline to week 26
  description: 
  measure: Mean change of motor function measure (MFM) D1 subscore (assessing standing
    and transfers)
overall_official:
- first_name: 
  last_name: Dirk Fischer, MD
  middle_name: 
  affiliation: University Children's Hospital Basel
  degrees: 
  role: Principal Investigator
phase: Phase 3
location_countries:
  country:
  - Switzerland
condition:
- Duchenne's Muscular Dystrophy (DMD)
clinical_results: {}
study_design: 'Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study,
  Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver,
  Investigator, Outcomes Assessor), Primary Purpose: Treatment'
keyword:
- Duchenne's muscular dystrophy
- DMD
results_reference: []
oversight_info:
  has_dmc: 'No'
  authority:
  - 'Switzerland: Swissmedic'
number_of_groups: 
location:
- status: Recruiting
  contact_backup: {}
  facility:
    name: University Children's Hospital
    address:
      city: Basel
      state: BS
      zip: '4031'
      country: Switzerland
  investigator:
  - first_name: 
    last_name: Dirk Fischer, MD
    middle_name: 
    affiliation: 
    degrees: 
    role: Principal Investigator
  - first_name: 
    last_name: Ulrike Bonati, MD
    middle_name: 
    affiliation: 
    degrees: 
    role: Sub-Investigator
  contact:
    first_name: 
    last_name: Ulrike Bonati, MD
    middle_name: 
    phone_ext: 
    phone: 
    degrees: 
    email: ulrike.bonati@ukbb.ch
  geodata:
    latitude: 47.557
    formatted: Basle, Switzerland
    longitude: 7.593
    original: Basel, BS
official_title: '"A Double Blind Randomised Placebo Controlled Efficacy and Safety
  Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years
  With Duchenne''s Muscular Dystrophy"'
verification_date: May 2015
required_header:
  url: https://clinicaltrials.gov/show/NCT01995032
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact:
  first_name: 
  last_name: Ulrike Bonati, MD
  middle_name: 
  phone_ext: 
  phone: "+41617042243"
  degrees: 
  email: ulrike.bonati@ukbb.ch
brief_title: L-citrulline and Metformin in Duchenne's Muscular Dystrophy
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
  - Muscular Dystrophy, Duchenne
brief_summary:
  textblock: |-
    The purpose of the study is to show that the intake of L-citrulline and metformin improves
          muscle function and delay of progression in patients with Duchenne's muscular dystrophy.
enrollment:
  attributes:
    type: Anticipated
  value: '50'
lastchanged_date: May 15, 2015
